Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galunisertib + gemcitabine
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Galunisertib + gemcitabine** is a combination of two drugs, galunisertib and gemcitabine, investigated for the treatment of unresectable pancreatic cancer. Galunisertib is a first-in-class oral small-molecule inhibitor targeting the transforming growth factor-beta receptor I (TGF-βRI/ALK5) serine/threonine kinase, blocking TGF-β signaling, which is implicated in the progression and resistance of several cancers, including pancreatic cancer. Gemcitabine is a nucleoside analog and antimetabolite chemotherapeutic that inhibits DNA synthesis. The combination has shown improved overall survival and progression-free survival compared to gemcitabine alone in phase II clinical trials for unresectable pancreatic cancer, with a manageable toxicity profile[1][2][3][4].
- Other names
- galunisertib + gemcitabine
02
Targets
ACVR1B (Activin A receptor type IB)TGFBR1TGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on galunisertib + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galunisertib + gemcitabine.